| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 | 4,356 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 | 3,472 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 | 884 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % | 19 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 | 473 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 | 39 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 | 0.66 |
Biocon
Biocon
386.10
+1.20
(0.31%)
Market Cap
₹51,620.17 Cr
PE Ratio
67.48
Volume
13,18,360.00
Day High - Low
₹388.70 - ₹383.75
52W High-Low
₹424.95 - ₹291.00
There are 3 new updates from the company1 day ago
View
Key Fundamentals
Market Cap
51,620.17 Cr
EPS
8.46
PB Ratio
1.92
Book Value
200.47
EBITDA
4,374.50
Dividend Yield
0.12 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.84
Analyst Rating and Forecast
- By Refinitiv from15 analysts
Actual
Company News
View All News
Biocon Biologics Named Asia IP Elite 2025 by IAM
21 hours ago
21 hours agoBiocon Biologics receives prestigious Asia IP Elite recognition from IAM for ninth consecutive year, highlighting exceptional intellectual property value creation and global biosimilars leadership.
CRISIL reaffirms Biocon's credit ratings with AA/Stable for long-term and A1+ for short-term on ₹250 crore bank facilities, maintaining strong creditworthiness profile.
Biocon Limited announces the launch of its GLP-1 peptide Liraglutide for diabetes and obesity treatment in the Netherlands through distribution partner Pharmamedicb B.V., marking its first EU launch under own brand after MEB approval.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,792.90 | #1 4,30,176.77 | 40.80 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 55.31 | |
6,293.00 | 1,67,059.38 | 67.69 | 9,712.00 | 18.67 | 2,191 | 35.10 | 40.39 | |
3,770.80 | 1,27,621.01 | 59.43 | 11,539.40 | 6.99 | 1,911 | 30.46 | 55.07 | |
1,496.90 | 1,20,912.71 | 22.30 | 28,409.50 | 7.12 | 5,291 | 3.71 | 42.59 | |
1,272.00 | 1,06,162.87 | 18.61 | 33,741.20 | 16.73 | 5,725 | -0.38 | 55.82 | |
2,113.10 | 96,516.80 | 21.96 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 62.97 | |
918.10 | 92,382.34 | #1 18.29 | 23,511.00 | 18.55 | 4,615 | 34.60 | 38.19 | |
2,111.20 | 87,141.57 | 49.02 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 26.69 | |
1,193.00 | 69,289.63 | 20.00 | 32,345.60 | 9.43 | 3,484 | 3.81 | 51.87 | |
5,628.50 | 67,297.16 | 28.08 | 13,458.30 | 3.70 | 2,216 | 10.98 | 48.73 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,823 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,038 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,448 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % | 54.45 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % | 6.61 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % | 22.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % | 12.71 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % | 4.12 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 | 4,13,191 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.13 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 31 Dec 2026 |  Extraordinary General Meeting | NA | 31 Dec 2026 | 392.80 | 384.90 |
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
| 01 Jul 2022 |  Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 04 Jul 2025 | Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 374.40 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 372.05 | 360.60 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 364.20 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 352.25 | 382.15 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release21 hours ago
21 hours agoAnnouncement under Regulation 30 (LODR)-Credit Rating1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Credit Rating1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Credit Rating7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoExtra-Ordinary General Meeting Scheduled To Be Held On Wednesday December 31 202510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Raising of FundsDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-Raising of FundsDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-AcquisitionDec 06, 2025
Dec 06, 2025Outcome Of Board MeetingDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 06, 2025
Dec 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 06, 2025
Dec 06, 2025Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI Listing Regulations 2015Dec 06, 2025
Dec 06, 2025Notification To Stock ExchangesDec 05, 2025
Dec 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 05, 2025
Dec 05, 2025Board Meeting Intimation for Intimation Of Board MeetingDec 03, 2025
Dec 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 02, 2025
Dec 02, 2025Company StatementNov 27, 2025
Nov 27, 2025NotificationNov 19, 2025
Nov 19, 2025Transcript Of Earnings Call Q2 FY26Nov 18, 2025
Nov 18, 2025Rumour verification - Regulation 30(11)Nov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Nov 13, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Nov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Raising of FundsNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsNov 11, 2025
Nov 11, 2025Outcome Of Board Meeting _ Early Full Redemption Of Non-Convertible DebenturesNov 11, 2025
Nov 11, 2025Outcome Of Board Meeting Held On November 11 2025Nov 11, 2025
Nov 11, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On November 11 2025Nov 11, 2025
Nov 11, 2025Financial Results For Quarter And Half Year Ended 30 September 2025Nov 11, 2025
Nov 11, 2025NotificationNov 08, 2025
Nov 08, 2025Update on board meetingNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Credit RatingOct 30, 2025
Oct 30, 2025Intimation Of Change In Status And Name Of Step-Down Subsidiary Of The CompanyOct 30, 2025
Oct 30, 2025Intimation Of Change In Name Of Step-Down Subsidiaries Of The CompanyOct 23, 2025
Oct 23, 2025Press ReleaseOct 23, 2025
Oct 23, 2025Press ReleaseOct 16, 2025
Oct 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Mutual Fund Holdings
SBI Large & Midcap Fund Direct Plan-Growth 
Nippon India Multi Cap Fund Direct-Growth 
ICICI Prudential Value Direct-Growth 
Tata Arbitrage Fund Direct - Growth 
Invesco India Arbitrage Fund Direct-Growth 
Axis Flexi Cap Fund Direct-Growth 
Bajaj Finserv Flexi Cap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
WhiteOak Capital Multi Asset Allocation Fund Direct - Growth 
Edelweiss Business Cycle Fund Direct-Growth 
HDFC Arbitrage Fund Wholesale Direct-Growth 
UTI Arbitrage Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 47.16
ATR(14)
Less Volatile 9.91
STOCH(9,6)
Neutral 24.06
STOCH RSI(14)
Neutral 28.81
MACD(12,26)
Bearish -2.21
ADX(14)
Weak Trend 16.59
UO(9)
Bearish 47.56
ROC(12)
Downtrend And Accelerating -3.38
WillR(14)
Neutral -74.70
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
11 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
